Signatera Oncology Test Drives Natera’s (NTRA) Growth

Core Insights - The fourth quarter of 2025 saw mixed results for midcap stocks, with the Russell Midcap® Growth Index decreasing by 3.70% and the Russell Midcap® Value Index increasing by 1.41% [1] - The Russell Midcap Growth Index rose by 8.66% in 2025, trailing the Russell Midcap Value Index's 11.04% return [1] - Carillon Eagle Mid Cap Growth Fund anticipates favorable equity market conditions and identifies potential opportunities in sectors such as Cyclicals, Healthcare, Information Technology, Financials, and Consumer Spending through 2026 [1] Company Insights: Natera, Inc. (NASDAQ:NTRA) - Natera, Inc. is highlighted as a leading contributor to the Carillon Eagle Mid Cap Growth Fund, specializing in ctDNA molecular testing services [2][3] - As of March 03, 2026, Natera's stock closed at $207.04 per share, with a one-month return of 0.70% and a 52-week gain of 39.97% [2] - Natera reported revenue of approximately $666 million in Q4 2025, representing a growth of around 40% compared to Q4 2024 [4] - The company’s flagship Signatera oncology test has driven growth, with volumes exceeding consensus estimates, leading to an increase in revenue growth guidance [3] - Natera's market capitalization stands at $28.872 billion, and it has shown strengthening profitability with rising gross margins and sustained positive free cash flow [2][3]